Avicanna's CEO Touts Q3 As 'Most Successful Quarter To Date' As It Posts Record Results, Expands Into 12th International Market

CBD-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE:0NN) reported its third-quarter financial results Friday, revealing a gross revenue increase of 24% sequentially and 260% compared to the first three months of 2021 to roughly CA$1,007,033 ($987,967).

The reported revenue represents cannabis-only sales, with the majority being new or recurring orders from proprietary finished products in the Canadian and adult-use channels, the Toronto-based company said.

Loss per share for the nine months ended September 31, 2021, was negative CA$0.29 per share, compared with negative CA$0.82 per share for the nine months ending September 30, 2020, representing an improvement of 64% from the same period in the previous year.

In addition, Avicanna also reported delivering 27,041 units of its cannabis 2.0 products branded as RHO Phyto and Pura Earth, compared to …

Full story available on Benzinga.com

More Avicanna's CEO Touts Q3 As 'Most Successful Quarter To Date' As It Posts Record Results, Expands Into 12th International Market